Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
Pink SheetWith 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe
ScripEli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet